| Literature DB >> 9207420 |
M J Dyer1, S M Kelsey, H J Mackay, E Emmett, P Thornton, G Hale, H Waldmann, A C Newland, D Catovsky.
Abstract
We assessed the role of human CD52 antibody (Campath-1H) in six patients with chronic lymphocytic leukaemia (CLL) treated to maximal response with purine analogues (fludarabine/deoxycoformycin) in whom persistent leukaemic infiltration of blood and bone marrow had precluded autologous stem cell transplantation. Five patients achieved haematological and histological complete remission following Campath-1H and one had minimal focal residual CLL in a trephine biopsy. Autologous transplantation was performed in two patients without complications and with rapid haemopoietic engraftment. Treatment with Campath-1H may be of value in eradicating residual disease in CLL and may facilitate high-dose therapy in young patients.Entities:
Mesh：
Substances：
Year: 1997 PMID： 9207420 DOI： 10.1046/j.1365-2141.1997.1062924.x
Source DB: PubMed Journal: Br J Haematol ISSN： 0007-1048 Impact factor: 6.998